SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 27, 2004
|
ImmunoGen, Inc. |
||||
|
(Exact name of registrant as specified in its charter) |
||||
|
|
||||
|
Massachusetts |
|
0-17999 |
|
04-2726691 |
|
(State or other |
|
(Commission |
|
(IRS Employer |
|
|
|
|
|
|
|
128 Sidney Street, Cambridge, MA 02139 |
||||
|
(Address of principal executive offices) (Zip Code) |
||||
|
|
||||
|
Registrant’s telephone number, including area code: (617) 995-2500 |
||||
|
|
||||
|
|
||||
|
(Former name or former address, if changed since last report) |
||||
Item 5. Other Events.
On May 27, 2004, ImmunoGen, Inc. announced that 4,030,000 shares of the 4,096,098 shares of its common stock held by Shire BioChem Inc. were placed with a third party institutional buyer. The press release announcing this event is incorporated herein by reference and filed as Exhibit 99.1 hereto.
Item 7. Financial Statements and Exhibits.
(c) Exhibits.
|
Exhibit No. |
|
Exhibit |
|
|
|
|
|
99.1 |
|
Press Release of ImmunoGen, Inc. dated May 27, 2004 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
ImmunoGen, Inc. |
|
|
|
|
(Registrant) |
||
|
|
|
||
|
|
|
||
|
Date: May 27, 2004 |
/s/ Virginia A. Lavery |
|
|
|
|
Virginia A. Lavery |
||
|
|
Vice President, Finance and |
||
|
|
Treasurer |
||
3